Impact of Rosuvastatin in post AMI/STEMI patients
Author(s):
Valon Asani, Atilla Rexhepi, Fisnik Demiri, Halit Sejfuli and Vlora Ibrahimi Ademi
Abstract:
In this synchronous – primary research, we tend to monitor for 6 months the effect of Rosuvastatin in patients that have been diagnosed with AMI/STEMI. Knowing that reducing and maintaining optimal lipid status in post AMI/PCI patients it is crucial, we want mathematically to verify the effect of Rosuvastatin in these patients.
How to cite this article:
Valon Asani, Atilla Rexhepi, Fisnik Demiri, Halit Sejfuli, Vlora Ibrahimi Ademi. Impact of Rosuvastatin in post AMI/STEMI patients. Pharma Innovation 2021;10(8):10-16.